A study of Aravive-S6 in acute myeloid leukemia (AML).
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Aravive S6 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 17 Jan 2017 New trial record
- 10 Jan 2017 According to an Aravive Biologics media release, company is planning to file an IND in late 2017.